2) This program is supported by educational grants from Pfizer & Incyte. Faculty disclosures https://t.co/UB9pTq270E. This program is intended for #healthcare providers. This is your ONLY #dermatology Twitter #CME/CE network: #physicians #physicianassociates #nurses #pharmacists
— @derm_ce (@derm_ce) May 23, 2022
4) The prevalence of #AD is estimated to be 15% to 20% in children & 1% to 3% in adults, although in the 🇺🇸 it's up to 7%. The disease course is commonly chronic in adults &more relapsing/remitting in children. See 🔓https://t.co/vhgzzzOv9b
— @derm_ce (@derm_ce) May 23, 2022
6) Childhood-onset #AD begins early in life, with 50% diagnosed in the 1st year of life & 85% by 5⃣ years of age. Adult-onset reported by 26% of adult patients with AD. Although AD often resolves during childhood, it persists through adulthood in 20% to 50% of patients. pic.twitter.com/8EotA6f3Po
— @derm_ce (@derm_ce) May 23, 2022
8) The “#atopic”(allergic) nature of #AD makes it different from other types of skin disorders as to causes, diagnosis, prevention, management & treatment.
AD is associated with an individual or family history of asthma, hay fever, food allergy &/or other allergic diseases. pic.twitter.com/k10aomSDIx— @derm_ce (@derm_ce) May 23, 2022
10) Diagnosis of #AD is made on the basis of clinical presentation & history, w/exclusion of multiple erythematous & eczematous conditions. Diagnosis is usu straightforward in infants & young children, but can be challenging in severe cases & in adults. 🔓https://t.co/Vs4zLUVzgq pic.twitter.com/4pHGUCHa1v
— @derm_ce (@derm_ce) May 23, 2022
12) An app is available to manage #atopic #dermatitis. PO-SCORAD, monitor the progression of AD and share photos with health care providers. Monitoring AD closely may make it easier to treat. Download for iOS, Android, Mac and Windows at https://t.co/htHwGTSskJ pic.twitter.com/Ur8RHTzesm
— @derm_ce (@derm_ce) May 23, 2022
14a) The pathogenesis of #AD is complex and involves multiple combinatorial factors, including genetic risk factors associated with immune dysregulation, mainly related to #type2 inflammation, and environmental stimuli . . .
— @derm_ce (@derm_ce) May 23, 2022
15) Accumulating evidence indicates that #AD expression is a precondition for the later development of other atopic diseases, such as #asthma, #food allergies, and #allergic #rhinitis. Cutaneous barrier dysfunction & immune dysregulation are critical etiologies of AD pathology.
— @derm_ce (@derm_ce) May 23, 2022
16b) . . . to produce Th2 cytokines such as IL-4, IL-5, & IL-13, leading to the secretion of #IgE from B cells. 🔓https://t.co/HccSwK3xEB pic.twitter.com/r2HWmYxFrr
— @derm_ce (@derm_ce) May 23, 2022
17b) . . . and infiltration of ILC2 in AD skin also contributes to elevation of IL-13 & IL-5 levels. 🔓https://t.co/WzYKzwJWd0 pic.twitter.com/G4N9PezcwD
— @derm_ce (@derm_ce) May 23, 2022
19) Mark your best response and return tomorrow for the correct answer and more education! It's all 🆓on your ONLY source of #accredited #tweetorials in #dermatology! 👍to @ProfPeteSmith @AIMedEdJC @florindanpopesq @allergytom @mrathkopf @JMDallergy @DrGerryLee @DrSamiraJeimy
— @derm_ce (@derm_ce) May 23, 2022
21) So did you answer yesterday's quiz? If not, please scroll back⤴️to # 18 before you scroll⤵️.
The answer is c; the other choices are indeed contributors to the #pathophysiology of #AD, but the colonization is typically with Staphylococcus aureus, not Strep spp.
Onward! pic.twitter.com/RFXyRUzHr6
— @derm_ce (@derm_ce) May 24, 2022
23) In 2020, European #recommendations, which are published every 2 years, guided the treatment of #AD. Depending on the AD severity, the algorithm in the recommendations describes treatment options at that moment. 🔓https://t.co/L5JTiYDDCf pic.twitter.com/PYUBat5CvI
— @derm_ce (@derm_ce) May 24, 2022
25) However, #AIT may be considered for selected patients w/ house dust mite, birch or grass pollen sensitization, who have severe AD & a history of clinical exacerbation after exposure to the causative allergen or a ➕ corresponding atopy patch test.
🔓https://t.co/jdCIpOWmNb pic.twitter.com/9TnDZTCEE8— @derm_ce (@derm_ce) May 24, 2022
27) In the recent past, new medications resulting from #immunological research have been licensed for #AD. The appearance of #biologics specific for immune mediators and receptors is extremely promising and some are now available for patients.
— @derm_ce (@derm_ce) May 24, 2022
29) #Nemolizumab, a subcutaneously administered humanized monoclonal antibody against IL-31 receptor A, & topical agents for AD resulted in a greater reduction in pruritus than the use of placebo and topical agents. See video at🔓https://t.co/ZbP82UL6bf
— @derm_ce (@derm_ce) May 24, 2022
31a) First-generation #JAKi are less selective & therefore demonstrate activity against 3 or all 4 members of the JAK enzyme family, whereas newer JAKi's display more selectivity for specific JAKs. Some JAK inhibitors were developed for the tx of #AD. 🔓https://t.co/JGJR4Cih5Q pic.twitter.com/iA3aGPbbue
— @derm_ce (@derm_ce) May 24, 2022
33) #JAK-1 activity is not only associated with #AD but also plays a role in the pathophysiology of other #skin #disorders such as #psoriasis, #dermatomyositis, #vitiligo, pruritus, lichen sclerosus, granuloma annulare, alopecia areata, #sarcoidosis, lichen planus…
— @derm_ce (@derm_ce) May 24, 2022
35) Phase II clinical trials with #abrocitinib have shown promising results with rapid improvement of clinical symptoms of #AD and #pruritus and very low rates of adverse effects. 🔓https://t.co/968HlHBTrV pic.twitter.com/gSQYAKBt9q
— @derm_ce (@derm_ce) May 24, 2022
36b) The proportion of patients who achieved an EASI-50 (A), EASI-75 (B), and EASI-90 (C) response over the 12-week treatment period is shown here: https://t.co/9GvVO4eSA1 pic.twitter.com/L27JHxsPsg
— @derm_ce (@derm_ce) May 24, 2022
38) It has a generally #safe profile and can be used in combination with topical #AD treatment, being effective and well tolerated in the adolescent and adult populations. pic.twitter.com/XaVayIcwIc
— @derm_ce (@derm_ce) May 24, 2022
40) In the JADE MONO-1 & JADE MONO-2 studies of #abrocitinib 100 mg versus 200 mg versus placebo, the onset of action was tremendously fast, leading to #itch ⬇️ within just a few days as well as a rapid ⬇️in the severity of #AD. 🔓https://t.co/fS787sY5VG pic.twitter.com/xU1fW55nMS
— @derm_ce (@derm_ce) May 24, 2022
42) The most frequent dose-related and drug-related reported side effects were mild, non-lethal ones, more frequently located at the respiratory and/or gastrointestinal level. pic.twitter.com/PVQGkZVXNw
— @derm_ce (@derm_ce) May 24, 2022
44) In Jan2022 FDA approved #abrocitinib for the treatment of adults living with refractory, moderate-to-severe #atopic #dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics. 🔓https://t.co/T87mCUvx0D pic.twitter.com/EhFgkU5iuc
— @derm_ce (@derm_ce) May 24, 2022
46) So the correct answer is d; the others may in fact be assoc'd with oral JAKi use. And that's it! You just earned 0.5h CE/#CME credit–get it NOW at https://t.co/6qPmqT52uG and keep your dial set to @derm_ce for more accredited programs by expert authors! I am @Aller_MD.
— @derm_ce (@derm_ce) May 24, 2022
